ArticleScientific reports2025
SDF-1α loaded lipid liquid crystalline hydrogel accelerates diabetic wound healing in in vitro and in vivo models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive Review of Hydrogel-Mediated Strategies for Diabetic Wound Healing.International journal of molecular sciences · 2026Review
- A Dual-Network Injectable Hydrogel Scaffold Integrating Glycyrrhizic Acid and Acellular Fat Extracts for Synergistic Enhancement of Diabetic Wound Healing.ACS polymers Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) significantly impairs wound healing, often leading to chronic wounds with limited effective treatment options. Existing treatments often fail to provide sustained therapeutic effects, underscoring the need for advanced biomaterial-based approaches to enhance tissue regeneration. This study aimed to evaluate the wound healing efficacy of stromal cell-derived factor-1 alpha (SDF-1α)-loaded lipid liquid crystalline (LLC) hydrogel in both in vitro and in vivo models. A scratch wound healing assay was conducted on human dermal fibroblast (HDF) cells treated with allantoin (100 µg), LLC hydrogel, SDF-1α 50 ng/LLC, SDF-1α 25 ng/LLC, SDF-1α 25 ng, and a negative control. In vivo studies utilized diabetic rats (n = 10 per group) with full-thickness wounds, treated with LLC hydrogel, SDF-1α 300 ng/LLC, and polyhexamethylene biguanide (PHMB), compared to a negative control. Wound closure rates were measured on days 3, 7, 14, and 21, and histopathological analysis was performed. The SDF-1α/LLC hydrogel significantly enhanced HDF cell migration, showing a 32.8% improvement over the control (P < 0.001). Diabetic wounds treated with SDF-1α/LLC hydrogel demonstrated 51.4% faster closure by day 14 compared to the control (P < 0.001), with complete closure achieved by day 21. By day 21, SDF-1α/LLC and LLC hydrogels achieved 100% wound closure, while PHMB-treated wounds also exhibited significant healing, reaching 97.86% closure. Histological analysis revealed increased fibroblast proliferation, reduced inflammation, enhanced collagen deposition, and greater epithelial thickness, particularly in the SDF-1α/LLC group. The SDF-1α-loaded LLC hydrogel significantly enhances fibroblast migration, accelerates wound closure, and promotes tissue regeneration, making it a promising candidate for diabetic wound care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.